FXR agonist obeticholic acid (OCA) can significantly improve the symptoms and liver function of patients with cholestasis who do not respond to ursodeoxycholic acid (UDCA) (Bowlus et al., 2019). The gene discussed is NR1H4; the disease is cholestasis.